MI-319 | MDM2 Antagonist

MedKoo Cat#: 564893 | Name: MI-319

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MI-319 is an MDM2 antagonist which restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.

Chemical Structure

MI-319

CAS#NONE

Theoretical Analysis

MedKoo Cat#: 564893

Name: MI-319

CAS#: NONE

Chemical Formula: C27H31Cl2F2N3O4

Exact Mass: 569.1660

Molecular Weight: 570.46

Elemental Analysis: C, 56.85; H, 5.48; Cl, 12.43; F, 6.66; N, 7.37; O, 11.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

MI319; MI 319; MI-319

IUPAC/Chemical Name

(2'R,3S,4'R,5'R)-6-chloro-4'-(3-chloro-4-fluorophenyl)-N-((S)-3,4-dihydroxybutyl)-5-fluoro-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide

InChi Key

SYCGJWKMQNLWAV-LYAXWJQESA-N

InChi Code

InChI=1S/C27H31Cl2F2N3O4/c1-26(2,3)11-21-27(15-9-19(31)17(29)10-20(15)33-25(27)38)22(13-4-5-18(30)16(28)8-13)23(34-21)24(37)32-7-6-14(36)12-35/h4-5,8-10,14,21-23,34-36H,6-7,11-12H2,1-3H3,(H,32,37)(H,33,38)/t14-,21+,22-,23+,27-/m0/s1

SMILES Code

O=C([C@H](N[C@@H]1CC(C)(C)C)[C@H](C2=CC=C(F)C(Cl)=C2)[C@]31C(NC4=C3C=C(F)C(Cl)=C4)=O)NCC[C@H](O)CO

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 570.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer. 2009 Dec 3;8:115. doi: 10.1186/1476-4598-8-115. PubMed PMID: 19958544; PubMed Central PMCID: PMC2794250. 2: Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer. 2010 Apr;46(6):1122-31. doi: 10.1016/j.ejca.2010.01.015. Epub 2010 Feb 13. PubMed PMID: 20156675; PubMed Central PMCID: PMC4106027. 3: Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010 May;10(3):319-31. PubMed PMID: 20370686; PubMed Central PMCID: PMC3809102. 4: Liu Q, Mier JW, Panka DJ. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Mol Cancer. 2011 Sep 19;10:115. doi: 10.1186/1476-4598-10-115. PubMed PMID: 21929745; PubMed Central PMCID: PMC3189171. 5: Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol. 2012 Sep 18;5:57. doi: 10.1186/1756-8722-5-57. PubMed PMID: 22989009; PubMed Central PMCID: PMC3473265. 6: Panka DJ, Liu Q, Geissler AK, Mier JW. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol Cancer. 2013 Mar 5;12:17. doi: 10.1186/1476-4598-12-17. PubMed PMID: 23497256; PubMed Central PMCID: PMC3637597. 7: Liu QJ, Shen HL, Lin J, Xu XH, Ji ZG, Han X, Shang DH, Yang PQ. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways. Drug Des Devel Ther. 2016 Feb 18;10:745-55. doi: 10.2147/DDDT.S88779. eCollection 2016. PubMed PMID: 26937175; PubMed Central PMCID: PMC4762585. 8: Tian X, Dai S, Sun J, Jiang S, Sui C, Meng F, Li Y, Fu L, Jiang T, Wang Y, Su J, Jiang Y. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53. Cell Physiol Biochem. 2016;39(5):2088-2098. Epub 2016 Oct 31. PubMed PMID: 27825169.